Cover Image
市場調查報告書

全球循環腫瘤細胞和癌症幹細胞技術

Circulating Tumor Cell (CTC) Diagnostics

出版商 Global Industry Analysts, Inc. 商品編碼 301517
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球循環腫瘤細胞和癌症幹細胞技術 Circulating Tumor Cell (CTC) Diagnostics
出版日期: 2017年02月01日 內容資訊: 英文 187 Pages
簡介

本報告提供全球循環腫瘤細胞和癌症幹細胞技術市場相關調查,提供各地區的總括性趨勢,彙整2013∼2020年的預測,加入此市場的企業簡介,為您概述為以下內容。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 循環腫瘤細胞(CTC):全球市場概要
    • CTC的檢測
    • CTC診斷的課題
    • CTC濃縮的必要性和公認的手法
    • CTC鑑定:各種方法
    • CTC鑑定方法
    • 市場預測
    • 癌症發病率上升
    • 各年齡層容易患癌的部位
  • 市場趨勢和促進因素
  • 癌症幹細胞:全球市場概要
    • 癌症治療上的癌症幹細胞技術創新
    • 癌症幹細胞候補的發展或分子標的
    • 眼科醫生治療細胞的開發平台分析
    • 對癌症幹細胞標記的標的毒性
    • 用於隔離癌症幹細胞所採用的各種方法
    • 抗體媒體治療
  • 循環腫瘤細胞和癌症幹細胞研究結果和劃時代的成果
  • 醫療診斷市場:概要
    • 臨床診斷
    • 分子診斷
    • 惡性淋巴腫瘤的分子診斷
    • 市場趨勢與課題
    • 全球急速成長中的分子診斷
    • 自動化促進市場發展及其他
  • 循環腫瘤細胞診斷:濃縮,鑑定,特性化手法
  • 癌症幹細胞:生物學,隔離,表面標誌物,信號傳達途徑
  • 產品上市和簡介
  • 近幾年的產業動向
  • 循環腫瘤細胞診斷的主要加入企業
    • Adnagen GmbH
    • ApoCell, Inc
    • Biocep LTD
    • Biocept, Inc.
    • Biofluidica Microtechnologies LLC
    • Celltrafix Inc.
    • Clearbridge Biomedics
    • Creatv Microtech, Inc
    • Cynvenio Biosystems, Inc.
    • Ikonisys, Inc.
    • IVDiagnostics, Inc.
    • Janssen Diagnostics LLC
    • Epic Biosciences Inc
    • RARECELLS SAS
    • SCREENCELL
    • Stemcell Technologies, Inc.
  • 癌症幹細胞領域的市場參與企業
    • Alchemia Limited
    • Amgen Inc.
    • Exelixis, Inc.
    • Formula Pharmaceuticals
    • GlaxoSmithKline Plc.
    • Geron Corp.
    • Infinity Pharmaceuticals
    • Kalobios Pharmaceuticals Inc.
    • Novartis AG
    • OncoMed Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Roche Diagnostics
    • Verastem, Inc.
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 其他

第4章 競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7869

This report analyzes the worldwide markets for Circulating Tumor Cell (CTC) Diagnostics in US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 48 companies including many key and niche players such as -

ApoCell, Inc.
Biocep Ltd.
Biocept, Inc.
Biofluidica Microtechnologies LLC
Celltraffix Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Market Outlook
  • Clinical Relevance of CTCs
  • CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
  • Major Challenges in CTC Diagnostics
  • Need for CTC Enrichment and Popular Methods
  • CTC Enrichment Techniques
  • Select Available CTC Detection Technologies
  • Select CTC Isolation Systems - A Brief Comparison
  • CTC Identification - Various Approaches
  • CTC Identification Approaches
  • List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
  • CellSearch System(tm) - The First FDA Approved Automated Enrichment/Isolation Technique
  • Rising Incidence of Cancer - An Opportunity Indicator
    • Table 1: Worldwide Incidence of Cancer (2013, 2020 & 2030): Number of New Cases Diagnosed (includes corresponding Graph/Chart)
    • Table 2: New Cancer Cases in the World by Affected Site (2012) (In Thousands) (includes corresponding Graph/Chart)
  • Cancer Prone Sites based on Age

2. MARKET TRENDS AND DRIVERS

  • Liquid Biopsy - the New Buzzword in Healthcare
  • Select Companies Active in Cancer Liquid Biopsy
  • CTCs for Personalized Cancer Treatment
  • Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
  • CTC Microdevices Hog the Limelight
    • Table 3: Select CTC Microdevices and Their Characteristics
  • Increasing Research Reveal Further Complexities to CTC Composition and Behavior
  • EpCAM Glycoprotein - Insufficient for CTC Detection
  • New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
  • Physical Property-based Enrichment Technologies Lose Fizz
  • Evidence in Favor CTC Heterogeneity Gains Strength
  • CTC Clusters Raise Research Interest
  • Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
  • Limitations of CTC Technology for Point-of- Care Testing
  • CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
  • Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
  • Select Research Findings in Recent Years
  • Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
  • NBiomics Makes its Contribution to CTC Diagnosis
  • Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
  • Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
  • Gold Nanoparticles Help in the Detection of CTCs

3. MEDICAL DIAGNOSTICS MARKET - A CONCEPTUAL OVERVIEW

  • Clinical Diagnostics
    • Table 4: Leading Players in the Global In Vitro Diagnostics (IVD) Market (2013) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)
    • Table 5: Global In-Vitro Diagnostics (IVD) Market (2013): Percentage Breakdown for Value Sales by Segment for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)
  • Molecular Diagnostics - Growth Drivers
  • Molecular Diagnostics for Lymphoid Malignancies
  • Market Trends & Issues
  • Global Molecular Diagnostics on a High Growth Curve
  • Automation Driving Global Market
  • Molecular Diagnostics: Marking Convergence of Numerous Technologies
  • Aging Population, Disease Incidence - Fundamental Drivers of Growth
  • Pharmaceutical Firms Carving their Niche in the Molecular Diagnostics Market
  • Limited Reimbursements by Third Party Payers - A Stumbling Block
  • Molecular Diagnostics and Intellectual Property
  • Business Opportunities in the Offing
  • Medical Training and Practice Challenges
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics
  • Integration of Molecular Diagnostics into Therapeutics
  • Molecular Diagnostics - Moving from Centralization to Decentralization

4. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS - ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS

  • Introduction
  • Enrichment
  • Filtration (iSET)
  • Density Gradient
  • Immuno-magnetic Cell Enrichment
    • Advantages of Different CTC Enrichment Procedures
  • AdnaTest
  • Identification
  • 1. PCR-Based Analysis
      • Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
      • RT-qPCR
  • 2. Cytometric Methods
      • Fiber-Optic Array Scanning Technology (FAST)
      • Laser Scanning Cytometry (LSC)
      • Flow Cytometry
      • CellSearch
      • Maintrac(r)
      • CTC-Chip
      • Enzyme-linked Epithelial Immunospot Assay (ELISPOT)
      • Fluorescence In Situ Hybridization (FISH)
      • Vita-Assay(r)
      • TelomeScan(tm)
      • CytoTrack
      • Some Other Methods for Detection of CTCs
  • Characterization
  • Chemo-Sensitivity Testing of CTCs

5. PRODUCT LAUNCHES AND INTRODUCTIONS

  • Vortex Biosciences Launches VTX-1 Liquid Biopsy System
  • Vortex Biosciences Secures CE Mark and FDA Class I Registration for VTX-1 Liquid Biopsy System
  • Fluxion Biosciences Roll Out New CTC Recovery Kits
  • Biocept Launches c-MET Amplification Detection Test
  • Biocept Launches ROS1 Test for Identifying Suitable Therapeutic Targets for NSCLC

6. RECENT INDUSTRY ACTIVITY

  • Menarini-Silicon Inks Agreement to Take Over CELLSEARCH(r) CTC Assets
  • Cancer Genetics and ApoCell Team Up for Cancer Profiling and Therapy Selection
  • Genomic Health Signs Commercial Agreement with Epic Sciences for AR-V7 Liquid Biopsy Test
  • BGI Joins Hands with Clearbridge BioMedics to Market CTC Products in China
  • Abnova Secures License to CSV Monoclonal Antibody for CTC Detection
  • Sorrento Secures License to CytoLumina's NanoVelcro CTC Profiling Assay
  • Janssen Announces Utility of CELLSEARCH(r) System in PD-L1 Expression Detection on CTCs
  • Qiagen Acquires AdnaGen's CTC Enrichment Technology
  • Tokai Inks Deal with Qiagen for Licensing CTC Enrichment Technology
  • ScreenCell Enters Collaborative Study for Evaluating CTC Enrichment Capability of ScreenCell Products

7. FOCUS ON SELECT PLAYERS

  • ApoCell, Inc. (US)
  • Biocep Ltd. (Israel)
  • Biocept, Inc. (US)
  • Biofluidica Microtechnologies LLC (US)
  • Celltraffix Inc. (US)
  • Clearbridge Biomedics (Singapore)
  • Creatv Microtech, Inc. (US)
  • Cynvenio Biosystems, Inc. (US)
  • Epic Biosciences Inc. (US)
  • Fluxion Biosciences, Inc. (US)
  • Ikonisys, Inc. (US)
  • IVDiagnostics, Inc. (US)
  • Janssen Diagnostics LLC (US)
  • QIAGEN Hannover GmbH (Germany)
  • RARECELLS SAS (Italy)
  • ScreenCell (France)
  • STEMCELL Technologies, Inc. (Canada)

8. GLOBAL MARKET PERSPECTIVE

    • Table 6: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 8: World 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US Diagnostics Market: An Overview
    • CTC Diagnostics in the US - Set for a Strong Growth
      • Approved CTC Tests in the US - A Brief Comparison
    • Cancer Incidence in the US
    • Table 9: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)
    • Table 10: Cancer Related Deaths by Gender in the US (2017E) (includes corresponding Graph/Chart)
    • Research Breakthroughs in the US CTC Market
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 11: The US Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 12: The US Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • Canadian Cancer Statistics
    • Table 13: New Cancer Cases in Canada (2016): Percentage Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)
    • Table 14: New Cancer Cases in Canada by Province (2016) (includes corresponding Graph/Chart)
    • Table 15: Cancer Incidence in Canada by Age Group and Gender: Age Standardized Incidence Rate per 100,000 People (2015) (includes corresponding Graph/Chart)
    • Stemcell Technologies, Inc. - A Key Player
  • B. Market Analytics
    • Table 16: Canadian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 17: Canadian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 18: Japanese Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 19: Japanese Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Insight into Molecular Diagnostics Markets in Europe
    • Cancer Trends
    • Table 20: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 21: European Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 22: European Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 23: European 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Analysis
    • ScreenCell - A Key Player
  • B. Market Analytics
    • Table 24: French Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 25: French Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • An Overview of Molecular Diagnostics Market
    • Strategic Corporate Development
    • Key Player
  • B. Market Analytics
    • Table 26: German Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 27: German Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current & Future Analysis
    • Rarecells Sas - A Key Player
  • B. Market Analytics
    • Table 28: Italian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 29: Italian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • Market Analysis
    • Table 30: The UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 31: The UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 32: Spanish Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 33: Spanish Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 34: Russian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 35: Russian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 36: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 37: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Cancer Trends in Asia-Pacific
    • Table 38: Cancer Incidence in Asia-Oceania by Site: 2011 (in Thousands) (includes corresponding Graph/Chart)
    • Indian Molecular Diagnostics Market
    • China
      • Chinese Cancer Statistics
    • Table 39: New Cancer Cases in China by Gender and Affected Site: 2015 (In Thousands) (includes corresponding Graph/Chart)
    • Table 40: Cancer Related Mortality in China by Gender and Affected Site: 2015 (In Thousands) (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Key Player
  • B. Market Analytics
    • Table 41: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 42: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
    • Key Player
  • B. Market Analytics
    • Table 43: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 44: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top